Dan brings to Caprion Proteomics deep industrial experience in applying the CellCarta® proteomics platform to drug target and biomarker discovery. Prior to joining the Company, Dan was President and General Manager of BioSignal Packard Inc. (a division of Perkin Elmer), where he oversaw the development of novel technologies and reagents for drug discovery and genomics research, including the AlphaScreenTM and BRET2TM technologies and product lines. Dan also spent five years at Pharmacopeia where, as Senior Director of Biology, his team identified many lead compounds from Pharmacopeia’s million member combinatorial chemistry libraries that resulted in multiple compounds in the clinic. His previous experience also includes positions at Onyx Pharmaceuticals and the DuPont Merck Pharmaceutical Company in cancer research. Dan received his B.Sc. from the University of California at Santa Barbara and his Ph.D. in Chemistry from the University Of Oregon Institute of Molecular Biology and was an American Cancer Society fellow at the University of California at Berkeley.

Dr. Cronin’s current position is Vice President of Translational Research at Genomic Health, Inc.  There she heads a team responsible for conducting initial feasibility research for new product concepts encompassing both technical and biological aspects of each concept including laboratory processes, automation systems, and data management with bioinformatics and biostatistical analyses.   All product concepts are focused on applying genomic biomarkers to provide clinically relevant molecular pathology tests for patient and physician clients.  Programs focus on delivering high throughput, high-performance, innovative, first-in-class medical products in a regulated reference laboratory environment.  Dr. Cronin brings 20 years of R&D experience in biotechnology companies focused on applying cutting edge technology to clinical diagnostics including ACLARA BioSciences, Protogene Laboratories and, Affymetrix where she played a key role in developing DNA microarray (GeneChipä) technology.  Dr. Cronin’s Ph.D. in Molecular Pharmacology is from the University of California, San Diego and her undergraduate education from the University of California, Davis.

Dr. Dhar is Deloitte’s Chief Medical Informatics Officer. He helps clients develop innovative strategies to improve clinical outcomes and therapeutic discovery. His translational informatics work is helping clients discover new approaches to optimize clinical R&D with breakthrough information management approaches. He has been retained by numerous provider systems, Cancer Centers, Life Science companies and Governmental Agencies to define translational research programs. Dr. Dhar is also a Senior Fellow with the Deloitte Center for Health Solutions. He developed the Center’s perspective on the ROI for Personalized Medicine with the Personalized Medicine Coalition which was presented at the American Association for the Advancement of Science. Dr. Dhar has deep functional and management experience that spans public and private sector clients. He has provided senior leadership for numerous Electronic Health Record (EHR) implementations in the US, Canada, and the UK. He has also helped design enterprise data warehousing solutions, clinical discovery applications, and quality improvement programs at large integrated delivery networks and academic medical institutions. Dr. Dhar has a deep experience in developing clinical and research informatics programs. He is a Senior Advisor to the FDA’s Enterprise Architecture team. He also has provided biomedical informatics advisory services for the National Cancer Institute (NCI) and has served on multiple study sections for the NIH National Human Genome Research Institute. Dr. Dhar holds a Medical Degree from the University of Illinois, a Masters in Business Administration degree from the University Of Chicago Booth School Of Business, and a Bachelor in Arts degree from the University of Chicago.

Professor Eddy Karnieli is a graduate of the Rappaport Faculty of Medicine at the Technion– Israel Institute of Technology in Haifa.He obtained clinical training in Internal Medicine and Endocrinology at the Rambam Medical Center and did his Post-Doctoral Fellowship in Diabetes, Obesity and Endocrinology at the National Institutes of Health in Bethesda, Maryland.
He was a visiting scholar at the University of California at San Diego and at the National Institutes of Health. He is currently the Director of the Institute of Endocrinology, Diabetes and Metabolism at the Rambam Medical Center. Professor Karnieli's main research interests are the molecular mechanisms for regulating cellular glucose uptake and transporters and their implications in diabetes, obesity and insulin resistance; Gene therapy modalities to trans-differentiate human cells toward beta-cells as a potential cure for type 1 diabetes; Medical informatics, telemedicine and personalized medicine. He has published about 70 peer reviewed papers and reviews.Professor Karnieli serves on the editorial board of several scientific journals and review boards. Professor Karnieli is a retired Colonel from the Israel Defense Forces Medical Corps and is a former Deputy Director of the Rambam Medical Center.

Mr. Kash is a co-founder and Partner of Two River. Since September 2004, Mr. Kash has served as the President of Two River's managing member, Two River Group Management, LLC, and served as its Chairman until April 2008. Mr. Kash is also the President and Chairman of Riverbank Capital Securities, Inc., a FINRA member broker dealer ("Riverbank") that has raised over $200 million since its inception in September 2005, including more than $80 million for Two River's Portfolio Companies. From 1992 until 2004, Mr. Kash was a Senior Managing Director of Paramount BioCapital, Inc., a FINRA member broker dealer, and Paramount BioCapital Investments, LLC, a biotechnology focused venture capital company. Mr. Kash also served as a member of the General Partner of the Orion Biomedical Fund, LP, a private equity fund. Mr. Kash currently serves as Chairman of the Board of Directors of Nile Therapeutics, Inc. (NASDAQ:NLTX) and as a director of Arno Therapeutics, Inc. (OTCBB:LRRI.OB), and Danube Pharmaceuticals, Inc. He was also a co-founder and former Vice Chairman of Javelin Pharmaceuticals, Inc. (AMEX:JAV). Mr. Kash served as an Adjunct Professor of Entrepreneurship and International Venture Capital at the Wharton School of Business at the University of Pennsylvania from 1996-2000. He was also Entrepreneur in Residence at Pace University and at Ball State University in May 2002. Mr. Kash served as a Professor of Entrepreneurship at the Sy Syms School of Business from 2003-2005, as well as Visiting Professor of Entrepreneurship at the Graduate School of Business at Nihon University in Tokyo. He is also the author of two books: Make Your Own Luck (2001 Prentice Hall), and Freedom From Disease (2008 - St. Martin's Press). Mr. Kash currently serves on the Board of Keren-Or, a charity for blind and multi-handicapped children, and is active in a variety of other charities, including Kids Kicking Cancer and Cancer Schmancer. He earned his B.S. in Management Science from SUNY Binghamton and his M.B.A. in Banking and International Finance from Pace University. He is currently writing his thesis for his Doctorate of Education.

Irene Norstedt has been working with various aspects of European Life Sciences research at the European Commission since 1996. She is currently Head of Sector for Medicines for the Future with key focus is on Personalized Medicine. Before that she was one of the key drivers for setting up the Innovative Medicines Initiative (IMI), a public private partnership between the EC and the Pharmaceutical industry. Previous responsibilities at the EC have primarily focussed on Small and Medium size Enterprises and industry aspects of biotechnology and health research at European level. Before starting her job in Brussels she worked for BIAcore AB in Uppsala, Sweden. There she had several positions including Business Development for the Drug Discovery and Food Analysis areas and Technical Services Manager. She has also worked as Assistant Technical Attaché at the Swedish Embassy in London. She has an MSc degree from the Royal Institute for Technology in Stockholm.

David Sidransky, M.D. was appointed the Chairman of the Board of Directors in October, 2007. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world, in the field of oncology during the past decade, with over 300 peer-reviewed publications. He has contributed more than 40 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as Vice Chairman of the Board of Directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is the Chairman of Alfacell Corporation and serves on the Board of Directors of Xenomics. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky serves as Director (2005-2008) of American Association for Cancer Research (AACR). He was the chairperson of AACR International Conferences (2006 and 2007) on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment. Dr. Sidransky is the recipient of a number of awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda and Richard Rosenthal Award from the American Association of Cancer Research. Dr. Sidransky received a B.A. from Brandeis University and M.D. from the Baylor College of Medicine.

Jayson Slotnik Health Policy Specialist, Foley Hoag

Jayson Slotnik serves as Counsel in the firm’s Government Strategies practice, where he advises clients on Medicare and Medicaid coverage, as well as reimbursement and coding issues covering medical devices, diagnostic tests, drugs, and biologics. Prior to joining Foley Hoag LLP, he worked as an Associate for other nationally renowned law firms advising both payors and innovators pertaining to Medicare and Medicaid payment and coverage issues. Previously, Jayson served as the initial Director of Medicare and Medicaid Reimbursement at the Biotechnology Industry Organization (BIO), the principal trade organization for the global biotech industry, handling matters relating to insurance coverage, coding and payment of drugs and biologics. He regularly represented the industry before the Center for Medicare and Medicaid Services, as well as Congress regarding coverage and reimbursement issues. In addition, Jayson advised BIO members on business development issues and worked with the membership and affiliate groups to develop innovator friendly policies related to complex diagnostic tests and other medical therapies. Prior to law school, Jayson gained extensive private sector healthcare experience. He worked as an epidemiologist designing scientific studies demonstrating clinical effectiveness of client products. As a senior analyst for a legislative firm, he monitored Medicaid and Medicare programs for healthcare technology clients with an eye towards expanding access to clients' therapies. He started his career as a reimbursement analyst for a pharmaceutical consulting firm counseling pharmaceutical and biotechnology companies on Medicare, Medicaid and other government reimbursement policies.

Keith Strier Principal & Partner, Health Sciences & Government Practice, Deloitte LLP

Keith Strier is a Principal/Partner with Health Sciences & Government Practice of Deloitte LLP and serves in numerous roles including Co-Leader, Health Informatics and Senior Fellow in Deloitte’s Washington, DC-based healthcare think tank, Center for Health Solutions. Keith advises Ministries of Health and Multi-National Corporations alike on biomedical innovation, personalized healthcare, translational medicine and globalization themes such as medical tourism and cross-border collaboration. Keith has been a Guest Faculty at the Harvard Medical School / MIT Health Science Technology Program, lecturing on healthcare innovation, since 2002. He also serves as a Strategic Advisor to Harvard Medical School’s Center for BioMedical Informatics. Keith has been a guest speaker at many prominent US academic institutions, including UCLA’s LA BioMedical Research Institute, UC Irvine’s Healthcare MBA Program, USC’s Global BioBusiness Initiative, UC Berkeley’s BioExec Institute, Claremont’s Keck School of Applied Sciences and at the Mayo Clinic’s Inaugural Symposium on Innovation in Healthcare. Internationally, Keith has been an invited speaker at the Summit on Information Systems in Translational Research at Seoul National University in Seoul, South Korea (2008), at Peking Union Medical Center in Beijing, China (2009) and at Amgen’s 2nd annual Oncology and Hematology Conference in Istanbul, Turkey (2010). Mr. Strier has a Bachelor’s of Science in Industrial & Labor Relations with Honors from Cornell University (1993) and a Law Degree from New York University’s School of Law (1996).

Patrick Terry, CEO of Technic Solutions, Co-Founder of Genomic Health, Founder of Personalized Medicine Coalition

Alan H.B. Wu, Ph.D. Professor of Laboratory Medicine, UCSF Pathology & Laboratory Medicine

Benny Schnaider was Qumranet's CEO and a Co-Founder. The company was acquired by Redhat in 2008. Benny was CEO and Co-Founder of PentaCom Ltd. a provider of networking products which was acquired by Cisco in 2000. Benny also co-founded and served on the Board of Directors for P-Cube, a developer of IP service control platforms, which was acquired by Cisco in 2004. Over the past 30 years, Benny has held senior management, engineering and strategic roles at many Silicon-Valley based companies including Cisco Systems, Amdahl/Fujitsu, Hitachi, IDT, Sun Microsystems and 3Com. Benny holds a Masters degree in Engineering Management from Santa Clara University, and a B.Sc in Computer Engineering from the Technion (Israel Institute of technology).